Halozyme Therapeutics (HALO) Quick Ratio: History & Chart

Halozyme Therapeutics, Inc.(HALO)

Biotechnology · San Diego, CA

$109.67+1.36 (+1.26%)

Delayed quote: Oct 6, 2026, 12:00 PM EDT

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

San Diego, CA

423 employees

www.halozyme.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Helen I. Torley

View full financials

HALO Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

2.31

QUICK RATIO (ACID-TEST) AVG TTM

3.34

QUICK RATIO (ACID-TEST) AVG 3Y

5.30

QUICK RATIO (ACID-TEST) AVG 5Y

5.68

QUICK RATIO (ACID-TEST) AVG 10Y

5.05

QUICK RATIO (ACID-TEST) AVG 15Y

4.95

QUICK RATIO (ACID-TEST) AVG 20Y

5.37

CURRENT VS TTM AVG

-30.74%

CURRENT VS 3Y AVG

-56.42%

CURRENT VS 5Y AVG

-59.29%

CURRENT VS 10Y AVG

-54.24%

CURRENT VS 15Y AVG

-53.28%

CURRENT VS 20Y AVG

-56.99%

SECTOR MEDIAN · HEALTHCARE

3.19

median of 727 covered companies

CURRENT VS SECTOR MEDIAN

-27.56%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Halozyme Therapeutics, Inc. (HALO)	$13.01B	2.31	3.34	5.30	5.68
Corcept Therapeutics Incorporated (CORT)vs ›	$12.88B	2.77	3.05	4.30	5.45
Tempus AI, Inc. (TEM)vs ›	$13.22B	3.16	2.58	2.23	3.05
BridgeBio Pharma, Inc. (BBIO)vs ›	$13.30B	1.17	3.59	3.76	4.72
Baxter International Inc. (BAX)vs ›	$12.52B	1.32	1.31	1.23	1.40
BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›	$12.51B	1.22	1.00	0.95	1.02
ICON Public Limited Company (ICLR)vs ›	$12.52B	0.95	1.18	1.19	1.30
Penumbra, Inc. (PEN)vs ›	$12.52B	3.86	3.87	3.53	3.55
Encompass Health Corporation (EHC)vs ›	$12.36B	1.19	1.06	1.17	1.20
Ascendis Pharma A/S (ASND)vs ›	$14.31B	2.32	0.80	0.84	4.11

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Halozyme Therapeutics, Inc. (HALO)

$13.01B

2.31

3.34

5.30

5.68

Corcept Therapeutics Incorporated (CORT)vs ›

$12.88B

2.77

3.05

4.30

5.45

Tempus AI, Inc. (TEM)vs ›

$13.22B

3.16

2.58

2.23

3.05

BridgeBio Pharma, Inc. (BBIO)vs ›

$13.30B

1.17

3.59

3.76

4.72

Baxter International Inc. (BAX)vs ›

$12.52B

1.32

1.31

1.23

1.40

BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›

$12.51B

1.22

1.00

0.95

1.02

ICON Public Limited Company (ICLR)vs ›

$12.52B

0.95

1.18

1.19

1.30

Penumbra, Inc. (PEN)vs ›

$12.52B

3.86

3.87

3.53

3.55

Encompass Health Corporation (EHC)vs ›

$12.36B

1.19

1.06

1.17

1.20

Ascendis Pharma A/S (ASND)vs ›

$14.31B

2.32

0.80

0.84

4.11

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Halozyme Therapeutics, Inc. (HALO)?

The quick ratio (acid-test) for HALO stock is 2.31.

Is Halozyme Therapeutics, Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 2.31 is 59% below its 5-year average of 5.68, near the low end of its 5-year range (1.37–9.15).

What is the TTM average quick ratio (acid-test) for Halozyme Therapeutics, Inc. (HALO)?

The TTM average quick ratio (acid-test) for HALO stock is 3.34.

What is the 3Y average quick ratio (acid-test) for Halozyme Therapeutics, Inc. (HALO)?

The 3Y average quick ratio (acid-test) for HALO stock is 5.30.

What is the 5Y average quick ratio (acid-test) for Halozyme Therapeutics, Inc. (HALO)?

The 5Y average quick ratio (acid-test) for HALO stock is 5.68.

What is the 10Y average quick ratio (acid-test) for Halozyme Therapeutics, Inc. (HALO)?

The 10Y average quick ratio (acid-test) for HALO stock is 5.05.

What is the 15Y average quick ratio (acid-test) for Halozyme Therapeutics, Inc. (HALO)?

The 15Y average quick ratio (acid-test) for HALO stock is 4.95.

What is the 20Y average quick ratio (acid-test) for Halozyme Therapeutics, Inc. (HALO)?

The 20Y average quick ratio (acid-test) for HALO stock is 5.37.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	2.31
2026-03-31	2.33
2025-12-31	3.66
2025-09-30	1.37
2025-06-30	7.01
2025-03-31	7.30
2024-12-31	6.78
2024-09-30	9.15
2024-06-30	6.21
2024-03-31	5.36
2023-12-31	5.50
2023-09-30	6.51
2023-06-30	5.44
2023-03-31	5.52
2022-12-31	4.88
2022-09-30	5.03
2022-06-30	2.23
2022-03-31	8.42
2021-12-31	7.45
2021-09-30	8.50
2021-06-30	8.24
2021-03-31	8.22
2020-12-31	1.17
2020-09-30	16.36
2020-06-30	17.34
2020-03-31	10.15
2019-12-31	6.00
2019-09-30	2.83
2019-06-30	2.57
2019-03-31	2.72
2018-12-31	2.71
2018-09-30	2.96
2018-06-30	3.43
2018-03-31	4.03
2017-12-31	3.85
2017-09-30	3.37
2017-06-30	3.94
2017-03-31	3.37
2016-12-31	4.43
2016-09-30	4.93
2016-06-30	7.04
2016-03-31	4.46
2015-12-31	2.60
2015-09-30	3.17
2015-06-30	4.59
2015-03-31	5.56
2014-12-31	6.37
2014-09-30	4.38
2014-06-30	5.31
2014-03-31	5.06
2013-12-31	3.50
2013-09-30	2.50
2013-06-30	2.98
2013-03-31	5.49
2012-12-31	6.77
2012-09-30	4.92
2012-06-30	7.30
2012-03-31	7.86
2011-12-31	3.67
2011-09-30	5.57
2011-06-30	2.79
2011-03-31	6.26
2010-12-31	5.82
2010-09-30	8.26
2010-06-30	4.36
2010-03-31	4.47
2009-12-31	5.09
2009-09-30	5.20
2009-06-30	6.12
2009-03-31	4.92
2008-12-31	5.17
2008-09-30	7.02
2008-06-30	9.08
2008-03-31	9.99
2007-12-31	11.33
2007-09-30	13.00
2007-06-30	17.05
2007-03-31	14.12
2006-12-31	10.62
2006-09-30	6.20
2006-06-30	6.61
2006-03-31	6.79
2005-12-31	8.61
2005-09-30	3.80
2005-06-30	6.13
2005-03-31	7.00
2004-12-31	10.19
2004-09-30	1.81
2004-06-30	4.66
2004-03-31	9.79
2003-12-31	1.27
2003-09-30	13.82
2003-06-30	15.27
2003-03-31	6.37
2002-12-31	9.32
2002-09-30	24.17

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

2.31

2026-03-31

2.33

2025-12-31

3.66

2025-09-30

1.37

2025-06-30

7.01

2025-03-31

7.30

2024-12-31

6.78

2024-09-30

9.15

2024-06-30

6.21

2024-03-31

5.36

2023-12-31

5.50

2023-09-30

6.51

2023-06-30

5.44

2023-03-31

5.52

2022-12-31

4.88

2022-09-30

5.03

2022-06-30

2.23

2022-03-31

8.42

2021-12-31

7.45

2021-09-30

8.50

2021-06-30

8.24

2021-03-31

8.22

2020-12-31

1.17

2020-09-30

16.36

2020-06-30

17.34

2020-03-31

10.15

2019-12-31

6.00

2019-09-30

2.83

2019-06-30

2.57

2019-03-31

2.72

2018-12-31

2.71

2018-09-30

2.96

2018-06-30

3.43

2018-03-31

4.03

2017-12-31

3.85

2017-09-30

3.37

2017-06-30

3.94

2017-03-31

3.37

2016-12-31

4.43

2016-09-30

4.93

2016-06-30

7.04

2016-03-31

4.46

2015-12-31

2.60

2015-09-30

3.17

2015-06-30

4.59

2015-03-31

5.56

2014-12-31

6.37

2014-09-30

4.38

2014-06-30

5.31

2014-03-31

5.06

2013-12-31

3.50

2013-09-30

2.50

2013-06-30

2.98

2013-03-31

5.49

2012-12-31

6.77

2012-09-30

4.92

2012-06-30

7.30

2012-03-31

7.86

2011-12-31

3.67

2011-09-30

5.57

2011-06-30

2.79

2011-03-31

6.26

2010-12-31

5.82

2010-09-30

8.26

2010-06-30

4.36

2010-03-31

4.47

2009-12-31

5.09

2009-09-30

5.20

2009-06-30

6.12

2009-03-31

4.92

2008-12-31

5.17

2008-09-30

7.02

2008-06-30

9.08

2008-03-31

9.99

2007-12-31

11.33

2007-09-30

13.00

2007-06-30

17.05

2007-03-31

14.12

2006-12-31

10.62

2006-09-30

6.20

2006-06-30

6.61

2006-03-31

6.79

2005-12-31

8.61

2005-09-30

3.80

2005-06-30

6.13

2005-03-31

7.00

2004-12-31

10.19

2004-09-30

1.81

2004-06-30

4.66

2004-03-31

9.79

2003-12-31

1.27

2003-09-30

13.82

2003-06-30

15.27

2003-03-31

6.37

2002-12-31

9.32

2002-09-30

24.17

Quick Ratio (Acid-Test): 2.31

HALO Quick Ratio

HALO Average Quick Ratio (Acid-Test) Chart

HALO Current vs Average Quick Ratio (Acid-Test) Chart

HALO Quick Ratio (Acid-Test) Metrics

HALO Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

HALO Quick Ratio (Acid-Test) History

Related Metrics